David Risinger Recent News
Large Option Trader Makes Aggressive Bearish Play On Teva
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality
Analysts Cut AbbVie Price Targets After Earnings Miss
Morgan Stanley Turns Bullish On Bausch Health: 'We Expect 2018 To Be The Last Year Of Declining Financials'
Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade
3 Headwinds Hindering Mylan
Morgan Stanley Initiates Amneal Pharmaceuticals, Anticipates Outperformance
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target
Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential
Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Analyst: Zoetis Deserves To Trade At A Premium
Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock
The Bull Thesis For Merck Is Evaporating
Pfizer Should Outperform, Morgan Stanley Upgrades
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
A Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley Downgrades
Merck's Leadership Position In Immuno Oncology Is Improving
Morgan Stanley Cuts Teva's Price Target By 33%
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong